In India, where 2.5 million people face cancer, a game-changing breakthrough has arrived. Meet NexCAR19—India’s first indigenous CAR T-cell therapy, developed by IIT Bombay and Tata Memorial Centre, and approved by the CDSCO.
NexCAR19 has shown impressive trial results: 67% of patients saw significant cancer reduction and 50% achieved complete remission. While similar therapies cost around ₹4 crore abroad, NexCAR19 will be available in India for a fraction of that price.
Patients can access this therapy immediately, bypassing long waits, and it showcases the power of local innovation in cancer care.
Swipe to learn more about this transformative therapy!
Click below to view all the images.
TA is a Bhopal-based policy and development consulting group. We are on a mission to make the development space more inclusive and democratic for students and professionals. Join us on this mission.
